However, relying on medication data to identify T2D cases may introduce misclassification bias as several antidiabetic medications such as metformin, glucagon-like peptide–1 receptor agonists, and sodium/glucose cotransporter 2 inhibitors are also prescribed for nondiabetic conditions, including polycystic ovary syndrome, obesity, and heart failure. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.